Cargando…
Measuring acute effects of subanesthetic ketamine on cerebrovascular hemodynamics in humans using TD-fNIRS
Quantifying neural activity in natural conditions (i.e. conditions comparable to the standard clinical patient experience) during the administration of psychedelics may further our scientific understanding of the effects and mechanisms of action. This data may facilitate the discovery of novel bioma...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10356754/ https://www.ncbi.nlm.nih.gov/pubmed/37468572 http://dx.doi.org/10.1038/s41598-023-38258-8 |
_version_ | 1785075343659368448 |
---|---|
author | Castillo, Adelaida Dubois, Julien Field, Ryan M. Fishburn, Frank Gundran, Andrew Ho, Wilson C. Jawhar, Sami Kates-Harbeck, Julian M. Aghajan, Zahra Miller, Naomi Perdue, Katherine L. Phillips, Jake Ryan, Wesley C. Shafiei, Mahdi Scholkmann, Felix Taylor, Moriah |
author_facet | Castillo, Adelaida Dubois, Julien Field, Ryan M. Fishburn, Frank Gundran, Andrew Ho, Wilson C. Jawhar, Sami Kates-Harbeck, Julian M. Aghajan, Zahra Miller, Naomi Perdue, Katherine L. Phillips, Jake Ryan, Wesley C. Shafiei, Mahdi Scholkmann, Felix Taylor, Moriah |
author_sort | Castillo, Adelaida |
collection | PubMed |
description | Quantifying neural activity in natural conditions (i.e. conditions comparable to the standard clinical patient experience) during the administration of psychedelics may further our scientific understanding of the effects and mechanisms of action. This data may facilitate the discovery of novel biomarkers enabling more personalized treatments and improved patient outcomes. In this single-blind, placebo-controlled study with a non-randomized design, we use time-domain functional near-infrared spectroscopy (TD-fNIRS) to measure acute brain dynamics after intramuscular subanesthetic ketamine (0.75 mg/kg) and placebo (saline) administration in healthy participants (n = 15, 8 females, 7 males, age 32.4 ± 7.5 years) in a clinical setting. We found that the ketamine administration caused an altered state of consciousness and changes in systemic physiology (e.g. increase in pulse rate and electrodermal activity). Furthermore, ketamine led to a brain-wide reduction in the fractional amplitude of low frequency fluctuations, and a decrease in the global brain connectivity of the prefrontal region. Lastly, we provide preliminary evidence that a combination of neural and physiological metrics may serve as predictors of subjective mystical experiences and reductions in depressive symptomatology. Overall, our study demonstrated the successful application of fNIRS neuroimaging to study the physiological effects of the psychoactive substance ketamine in humans, and can be regarded as an important step toward larger scale clinical fNIRS studies that can quantify the impact of psychedelics on the brain in standard clinical settings. |
format | Online Article Text |
id | pubmed-10356754 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-103567542023-07-21 Measuring acute effects of subanesthetic ketamine on cerebrovascular hemodynamics in humans using TD-fNIRS Castillo, Adelaida Dubois, Julien Field, Ryan M. Fishburn, Frank Gundran, Andrew Ho, Wilson C. Jawhar, Sami Kates-Harbeck, Julian M. Aghajan, Zahra Miller, Naomi Perdue, Katherine L. Phillips, Jake Ryan, Wesley C. Shafiei, Mahdi Scholkmann, Felix Taylor, Moriah Sci Rep Article Quantifying neural activity in natural conditions (i.e. conditions comparable to the standard clinical patient experience) during the administration of psychedelics may further our scientific understanding of the effects and mechanisms of action. This data may facilitate the discovery of novel biomarkers enabling more personalized treatments and improved patient outcomes. In this single-blind, placebo-controlled study with a non-randomized design, we use time-domain functional near-infrared spectroscopy (TD-fNIRS) to measure acute brain dynamics after intramuscular subanesthetic ketamine (0.75 mg/kg) and placebo (saline) administration in healthy participants (n = 15, 8 females, 7 males, age 32.4 ± 7.5 years) in a clinical setting. We found that the ketamine administration caused an altered state of consciousness and changes in systemic physiology (e.g. increase in pulse rate and electrodermal activity). Furthermore, ketamine led to a brain-wide reduction in the fractional amplitude of low frequency fluctuations, and a decrease in the global brain connectivity of the prefrontal region. Lastly, we provide preliminary evidence that a combination of neural and physiological metrics may serve as predictors of subjective mystical experiences and reductions in depressive symptomatology. Overall, our study demonstrated the successful application of fNIRS neuroimaging to study the physiological effects of the psychoactive substance ketamine in humans, and can be regarded as an important step toward larger scale clinical fNIRS studies that can quantify the impact of psychedelics on the brain in standard clinical settings. Nature Publishing Group UK 2023-07-19 /pmc/articles/PMC10356754/ /pubmed/37468572 http://dx.doi.org/10.1038/s41598-023-38258-8 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Castillo, Adelaida Dubois, Julien Field, Ryan M. Fishburn, Frank Gundran, Andrew Ho, Wilson C. Jawhar, Sami Kates-Harbeck, Julian M. Aghajan, Zahra Miller, Naomi Perdue, Katherine L. Phillips, Jake Ryan, Wesley C. Shafiei, Mahdi Scholkmann, Felix Taylor, Moriah Measuring acute effects of subanesthetic ketamine on cerebrovascular hemodynamics in humans using TD-fNIRS |
title | Measuring acute effects of subanesthetic ketamine on cerebrovascular hemodynamics in humans using TD-fNIRS |
title_full | Measuring acute effects of subanesthetic ketamine on cerebrovascular hemodynamics in humans using TD-fNIRS |
title_fullStr | Measuring acute effects of subanesthetic ketamine on cerebrovascular hemodynamics in humans using TD-fNIRS |
title_full_unstemmed | Measuring acute effects of subanesthetic ketamine on cerebrovascular hemodynamics in humans using TD-fNIRS |
title_short | Measuring acute effects of subanesthetic ketamine on cerebrovascular hemodynamics in humans using TD-fNIRS |
title_sort | measuring acute effects of subanesthetic ketamine on cerebrovascular hemodynamics in humans using td-fnirs |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10356754/ https://www.ncbi.nlm.nih.gov/pubmed/37468572 http://dx.doi.org/10.1038/s41598-023-38258-8 |
work_keys_str_mv | AT castilloadelaida measuringacuteeffectsofsubanestheticketamineoncerebrovascularhemodynamicsinhumansusingtdfnirs AT duboisjulien measuringacuteeffectsofsubanestheticketamineoncerebrovascularhemodynamicsinhumansusingtdfnirs AT fieldryanm measuringacuteeffectsofsubanestheticketamineoncerebrovascularhemodynamicsinhumansusingtdfnirs AT fishburnfrank measuringacuteeffectsofsubanestheticketamineoncerebrovascularhemodynamicsinhumansusingtdfnirs AT gundranandrew measuringacuteeffectsofsubanestheticketamineoncerebrovascularhemodynamicsinhumansusingtdfnirs AT howilsonc measuringacuteeffectsofsubanestheticketamineoncerebrovascularhemodynamicsinhumansusingtdfnirs AT jawharsami measuringacuteeffectsofsubanestheticketamineoncerebrovascularhemodynamicsinhumansusingtdfnirs AT katesharbeckjulian measuringacuteeffectsofsubanestheticketamineoncerebrovascularhemodynamicsinhumansusingtdfnirs AT maghajanzahra measuringacuteeffectsofsubanestheticketamineoncerebrovascularhemodynamicsinhumansusingtdfnirs AT millernaomi measuringacuteeffectsofsubanestheticketamineoncerebrovascularhemodynamicsinhumansusingtdfnirs AT perduekatherinel measuringacuteeffectsofsubanestheticketamineoncerebrovascularhemodynamicsinhumansusingtdfnirs AT phillipsjake measuringacuteeffectsofsubanestheticketamineoncerebrovascularhemodynamicsinhumansusingtdfnirs AT ryanwesleyc measuringacuteeffectsofsubanestheticketamineoncerebrovascularhemodynamicsinhumansusingtdfnirs AT shafieimahdi measuringacuteeffectsofsubanestheticketamineoncerebrovascularhemodynamicsinhumansusingtdfnirs AT scholkmannfelix measuringacuteeffectsofsubanestheticketamineoncerebrovascularhemodynamicsinhumansusingtdfnirs AT taylormoriah measuringacuteeffectsofsubanestheticketamineoncerebrovascularhemodynamicsinhumansusingtdfnirs |